Johnson & Johnson Vision Receives Approval in Canada for ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management
- First daily wear lens developed by Johnson & Johnson Vision as a breakthrough innovation specifically designed for slowing the progression of myopia in children
- Expands the growing portfolio of myopia management products and services from Johnson & Johnson Vision
- Soft contact lenses with novel ring focus technology may help address the progression of myopia in children1
- Made of silicone hydrogel (senofilcon A) lens material, the same material as ACUVUE® OASYS 1-Day contact lenses, which have never been beaten in comfort
JACKSONVILLE, FL – September 8, 2021 – Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies‡, received approval from Health Canada for ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management. Abiliti™ 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifically designed for children who are 7 to 12 years old at the start of treatment.